RNXT surges 43% as EPS revisions lift penny stocks
RenovoRx Inc (RNXT) led all gainers, jumping 43.1% from $1.67 to $2.39 on August 28 after analysts raised its next-year EPS growth estimate by 5.6 percentage points to 46.7%. Montauk Renewables (MNTK) and Faeth Therapeutics (FTH) also posted double-digit gains post-revision, while DeFi Development (DFDV) and Robinhood (HOOD) surged on solid fundamentals and crypto tailwinds, with HOOD up 17.1% to lead the S&P 500.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| RNXT | Healthcare | 2026-08-28 | +5.6pp | +43.1% |
| MNTK | Basic Materials | 2026-09-01 | N/A | +26.7% |
| FTH | Healthcare | 2026-08-30 | +1.2pp | +18.4% |
| DFDV | Financial | 2026-08-29 | +6.9pp | +17.9% |
| HOOD | Financial | 2026-08-28 | N/A | +17.1% |
Why did RNXT stock jump in September 2026?
RNXT jumped 43.1% (from $1.67 to $2.39) after analysts raised its forward EPS growth estimate from 41.1% to 46.7% on August 28.
The revision came without any accompanying earnings news, suggesting the move was driven purely by improving sell-side expectations for the healthcare micro-cap. Detected by our screener the same day, the price surge validates the EPS revision as a leading indicator. Such a large upward revision in growth estimates often precedes institutional accumulation in small biotechs.
RNXT EPS revision history → · Screener snapshot from 2026-08-28 →
FAQ: RNXT
Why did RNXT stock jump in September 2026?
RNXT jumped 43.1% to $2.39 after analysts boosted its next-year EPS growth estimate from 41.1% to 46.7%, a revision detected on August 28.
Is RNXT a buy after the rally?
The EPS revision and price surge signal improving fundamentals, but at $2.39 with a 43% gain, investors should weigh the sustainability of the growth estimate against micro-cap volatility.
What is RNXT's EPS growth estimate?
RNXT's next-year EPS growth estimate stands at 46.7%, up from 41.1% a week earlier.
Why did MNTK stock jump in September 2026?
MNTK (Montauk Renewables) advanced 26.7% from $1.76 to $2.23 after its current EPS growth estimate for next year hit 35.3% as of September 1.
The gain in the basic materials sector came with no direct earnings news, pointing to a broader re-rating of renewable energy names amid policy tailwinds. Our screener flagged the revision before the price move, confirming that earnings momentum often precedes market recognition. The stock's low price suggests retail interest, but the EPS trajectory supports the rally.
MNTK EPS revision history → · Screener snapshot from 2026-09-01 →
FAQ: MNTK
Why did MNTK stock jump in early September 2026?
MNTK rose 26.7% to $2.23 after its next-year EPS growth estimate reached 35.3%, reflecting improved sell-side expectations for the renewable energy firm.
Is MNTK a buy after the rally?
Given the strong EPS revision and positive momentum in basic materials, MNTK could have upside, but investors should monitor the renewable energy sector's policy environment.
What is MNTK's EPS growth estimate?
MNTK's current EPS growth for next year is estimated at 35.3%.
Why did FTH stock jump in September 2026?
FTH (Faeth Therapeutics) gained 18.4% from $33.84 to $40.05 after analysts revised its forward EPS growth upward from 77.6% to 78.7% on August 30.
This small yet meaningful upgrade in the healthcare sector came with no company-specific news, suggesting the move was driven by pipeline or consensus modeling changes. The stock's jump validates the screener's 1.2 percentage-point revision signal. Investors in high-growth biotechs often react swiftly to even fractional EPS estimate improvements.
FTH EPS revision history → · Screener snapshot from 2026-08-30 →
FAQ: FTH
Why did FTH stock jump in late August 2026?
FTH rose 18.4% to $40.05 after its next-year EPS growth estimate was revised up to 78.7% from 77.6% on August 30.
Is FTH a buy after the rally?
The upward revision signals strong expected growth, but the 18.4% jump already prices in much of the optimism; watch for continued accuracy in earnings execution.
What is FTH's EPS growth estimate?
FTH's next-year EPS growth estimate is now 78.7%, up 1.2 percentage points from 77.6%.
Why did DFDV stock jump in September 2026?
DFDV (DeFi Development Corp.) jumped 17.9% (from $4.98 to $5.87) after its forward EPS growth estimate was revised up from 74.1% to 81.0% on August 29, and news confirmed the bullish thesis.
The company announced a preferred stock offering to raise up to $19.8 million to buy more Solana (SOL), and disclosed holdings of 2.33 million SOL worth about $236 million. Our screener caught the six-point revision before the price action, which was reinforced by the crypto treasury strategy gaining traction. The offering, which partly funds SOL purchases, aligns with the EPS upgrade.
DFDV EPS revision history → · Screener snapshot from 2026-08-29 →
FAQ: DFDV
Why did DFDV stock jump in September 2026?
DFDV rose 17.9% to $5.87 after analysts boosted its next-year EPS growth estimate to 81.0% from 74.1%, and the company announced an $11M raise to expand its Solana treasury.
Is DFDV a buy after the rally?
With EPS growth estimates at 81% and a clear SOL accumulation strategy, DFDV offers high-growth potential, but its fortunes are tied to Solana's price and crypto market volatility.
What caused DFDV's surge?
The surge was driven by the EPS growth upgrade from 74.1% to 81.0%, combined with news of its preferred stock offering to increase SOL holdings.
Why did HOOD stock jump in September 2026?
HOOD (Robinhood Markets) jumped 17.1% from $104.26 to $122.11, making it the S&P 500's top gainer on September 3, after the current EPS growth estimate for next year held at 34.1% and analysts turned bullish.
Morgan Stanley upgraded the stock to 'overweight' with a $150 price target, and Scotiabank initiated with a positive view, citing asset growth and wallet share gains. Bitcoin's climb toward $81,500 also lifted crypto-exposed names, including an 18% rally in Strategy (MSTR). The combination of earnings estimate strength, analyst upgrades, and crypto momentum powered the move.
HOOD EPS revision history → · Screener snapshot from 2026-08-28 →
FAQ: HOOD
Why did HOOD stock jump in September 2026?
HOOD rose 17.1% to $122.11, the best in the S&P 500, amid analyst upgrades from Morgan Stanley (target $150) and Scotiabank, plus a surge in bitcoin to $81,500.
Is HOOD a buy after the rally?
With an EPS growth estimate of 34.1% and bullish analyst targets, HOOD appears well-positioned, but investors should monitor crypto volatility and trading volumes.
What is HOOD's EPS growth estimate?
HOOD's current EPS growth for next year is estimated at 34.1%.
Today's top movers show that upward EPS revisions continue to signal strong price gains, with the most dramatic moves in small caps like RNXT and DFDV. The blend of analyst upgrades, crypto momentum, and pure revision-driven rallies suggests a market that rewards stocks with improving earnings trajectories.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →